Señales en vivo de AVCT.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:44):

Stats
Volumen de hoy	5.64M
Volumen promedio	3.20M
Capitalización de mercado	159.86M
EPS	£0 ( 2024-04-22 )
Próxima fecha de ganancias	( £0 ) 2024-04-30
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-3.05
ATR14	£0.191 (0.39%)

Volumen Correlación

Largo: -0.30 (neutral)

Corto: 0.96 (very strong)

Signal:(49.348) Expect same movement, but be aware

Avacta Group PLC Correlación

10 Correlaciones Más Positivas
TEM.L	0.92
JAGI.L	0.92
XMMS.L	0.893
FCSS.L	0.889
HSXJ.L	0.885
EMIM.L	0.885
JMG.L	0.883
FEMS.L	0.88
AEMD.L	0.876
LAND.L	0.875

10 Correlaciones Más Negativas
SJPY.L	-0.894
3EMS.L	-0.841
NWF.L	-0.822
ARC.L	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Avacta Group PLC Correlación - Moneda/Commodity

-0.27
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.04
( neutral )

-0.18
( neutral )

Avacta Group PLC Finanzas

Annual	2022
Ingresos:	£9.65M
Beneficio Bruto:	£4.23M (43.83 %)
EPS:	£-0.150

FY	2022
Ingresos:	£9.65M
Beneficio Bruto:	£4.23M (43.83 %)
EPS:	£-0.150

FY	2021
Ingresos:	£2.94M
Beneficio Bruto:	£2.02M (68.58 %)
EPS:	£-0.106

FY	2020
Ingresos:	£3.64M
Beneficio Bruto:	£2.18M (59.98 %)
EPS:	£-0.0837

Financial Reports:

No articles found.

Avacta Group PLC

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Actualizaciones en tiempo real para Avacta Group PLC [AVCT.L]

Upcoming Earnings Alert